1
|
Thonhauser R, Poglitsch M, Jonas JP, Dong Y, Tschögl M, Gramberger M, Salem M, Santol J, Brandl I, Klimpfinger M, Vierziger C, Gruenberger T. The Effect of Induction Chemotherapy with VEGF Inhibition on Tumor Response in Synchronously Metastasized Potentially Resectable Colorectal Cancer. Cancers (Basel) 2023; 15:cancers15112900. [PMID: 37296862 DOI: 10.3390/cancers15112900] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2023] [Revised: 05/13/2023] [Accepted: 05/19/2023] [Indexed: 06/12/2023] Open
Abstract
(1) Background: The pathological tumor response of the primary tumor to induction chemotherapy in synchronously metastasized colorectal cancer (mCRC) patients has not been investigated. The aim of this study was to compare patients treated with induction chemotherapy combined with vascular endothelial growth factor (VEGF) or with epidermal growth factor receptor (EGFR) antibodies. (2) Methods: We present a retrospective analysis, where we included 60 consecutive patients with potentially resectable synchronous mCRC who received induction chemotherapy combined with either VEGF or EGFR antibodies. The primary endpoint of this study was the regression of the primary tumor, which was assessed by the application of the histological regression score according to Rödel. The secondary endpoints were recurrence-free survival (RFS) and overall survival (OS). (3) Results: A significantly better pathological response and a longer RFS for patients treated with the VEGF antibody therapy compared to those treated with the EGFR antibodies was demonstrated (p = 0.005 for the primary tumor and log-rank = 0.047 for RFS). The overall survival did not differ. The trial was registered with clinicaltrial.gov, number NCT05172635. (4) Conclusion: Induction chemotherapy combined with a VEGF antibody revealed a better pathological response of the primary tumor, leading to a better RFS compared to that with EGFR therapy; this has clinical relevance in patients with potentially resectable synchronously mCRC.
Collapse
Affiliation(s)
- Rebecca Thonhauser
- Department of Surgery, HPB Center, Clinic Favoriten, 1100 Vienna, Austria
| | - Marcus Poglitsch
- Department of Surgery, HPB Center, Clinic Favoriten, 1100 Vienna, Austria
| | - Jan Philipp Jonas
- Department of Surgery, HPB Center, Clinic Favoriten, 1100 Vienna, Austria
| | - Yawen Dong
- Department of Surgery, HPB Center, Clinic Favoriten, 1100 Vienna, Austria
| | - Madita Tschögl
- Department of Surgery, HPB Center, Clinic Favoriten, 1100 Vienna, Austria
| | - Mariel Gramberger
- Department of Surgery, HPB Center, Clinic Favoriten, 1100 Vienna, Austria
| | - Mohamed Salem
- Department of Surgery, HPB Center, Clinic Favoriten, 1100 Vienna, Austria
| | - Jonas Santol
- Department of Surgery, HPB Center, Clinic Favoriten, 1100 Vienna, Austria
| | - Irmgard Brandl
- Institute of Pathology and Bacteriology, Clinic Favoriten, 1100 Vienna, Austria
| | - Martin Klimpfinger
- Institute of Pathology and Bacteriology, Clinic Favoriten, 1100 Vienna, Austria
| | - Constantin Vierziger
- Institute for Diagnostic and Interventional Radiology, Clinic Favoriten, 1100 Vienna, Austria
| | - Thomas Gruenberger
- Department of Surgery, HPB Center, Clinic Favoriten, 1100 Vienna, Austria
| |
Collapse
|